ClinicalTrials.gg
Not yet recruitingNCT07855562Updated Oct 2, 2026

MPS IIIA Disease Monitoring Program

An observational study in MPS IIIA, Sanfilippo Syndrome and Sanfilippo A, sponsored by Ultragenyx Pharmaceutical Inc. Not yet recruiting. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Ultragenyx Pharmaceutical Inc · Observational

How we know

Updated Oct 2, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
55
Sex
All
01

Study summary

The main objective of this observational study is to evaluate the long-term safety and effectiveness of rebisufligene etisparvovec for 10 years after rebisufligene etisparvovec administration.

Read the detailed description

The UX111-CL401 MPS IIIA Disease Monitoring Program is a prospective, multicenter, long term outcomes study to obtain safety and clinical outcomes data for 10 years after the administration of rebisufligene etisparvovec in either a clinical trial or post-marketing setting.

02

Conditions studied

  • MPS IIIA
  • Sanfilippo Syndrome
  • Sanfilippo A
  • Mucopolysaccharidosis III

Keywords

  • MPS IIIA
  • Sanfilippo
  • Gene Therapy
03

In context

Mucopolysaccharidosis III

58 studies on the registry are indexed under Mucopolysaccharidosis III; 16 are open to participants now.

This study's planned enrollment of 55 is above the median of 30 across 24 observational studies indexed under Mucopolysaccharidosis III.

Browse Mucopolysaccharidosis III studies →

Lead sponsor

Ultragenyx Pharmaceutical Inc is the lead sponsor of 63 studies on the registry; 8 are open to participants now.

Of its 16 completed or terminated interventional studies of FDA-regulated products, 12 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The DMP population comprises patients with MPS IIIA who received rebisufligene etisparvovec in a clinical trial or have been prescribed (or plan to receive) rebisufligene etisparvovec in a post marketing setting.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of MPS IIIA
  • Patient who:

    1. Group 1: Received rebisufligene etisparvovec in a prior interventional clinical trial.

      May be enrolled upon completion of Study ABT-001 (Cohort 4) or end of study (EOS) or early termination (ET) visit from the prior clinical trial (Study ABT-003 or Study LTFU-ABO-102). OR

    2. Group 2: Received (or plans to receive) rebisufligene etisparvovec in a postmarketing setting.
  • Provide after the nature of the study has been explained, and prior to any research-related procedures. If a minor or an adult with cognitive limitations, willing and able (if possible) to provide assent and have a legally authorized representative provide informed consent after the nature of the study has been explained, and prior to any research-related procedures.

Exclusion criteria

Exclusion Criteria:

  • Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
55 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Rebisufligene Etisparvovec in Prior Clinical Study

    Participants administered rebisufligene etisparvovec (Fayuvi, UX111) in prior clinical study involving rebisufligene etisparvovec

    Other: No Intervention

  • Group 2: Rebisufligene Etisparvovec in Post-Marketing Setting

    Participants administered rebisufligene etisparvovec (Fayuvi, UX111) in a post-marketing setting

    Other: No Intervention

Interventions

  • OtherNo Intervention

    No investigational/study product will be administered in this DMP.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Serious Adverse Events (SAEs) Assessed as Related to Rebisufligene Etisparvovec by the Investigator and Targeted Adverse Events (Targeted AEs) Associated with Identified and Potential Risks of UX111 or AAV8 Gene Therapy

    Time frame: 10 Years

  2. Bayley Scales of Infant and Toddler Development Cognitive Raw Score Over Time

    Time frame: 10 Years

07

Study locations

No study locations are listed for this record.

08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Oct 2038, 143 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2026
First posted
Oct 2, 2026
StartEst.
Nov 2026
Primary completionEst.
Oct 2038
CompletionEst.
Oct 2038
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07855562
Responsible party
Sponsor
First posted
Oct 2, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2038 (estimated)
Completion
Oct 2038 (estimated)
Last update
Oct 2, 2026

Study contacts

Patients Contact: Trial Recruitment
Contact
trialrecruitment@ultragenyx.com
1-888-756-8657
HCPs Contact: Medical Information
Contact
medinfo@ultragenyx.com
1-888-756-8657
Medical Director
study director · Ultragenyx Pharmaceuticals Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion